Memorial Sloan Kettering Cancer Center;Eureka Therapeutics, Inc.
发明人:
申请号：
EP15864773.5
公开号：
EP3227436A4
申请日:
2015.12.04
申请国别(地区):
EP
年份:
2018
代理人:
摘要：
The presently disclosed subject matter provides for methods and compositions for treating a neoplasia (e.g., multiple myeloma). It relates to chimeric antigen receptors (CARs) that specifically target Fc Receptor-like 5 (FcRL5), e.g., domain 9 of FcRL5, and immunoresponsive cells comprising such CARs. The presently disclosed FcRL5-targeted CARs have enhanced immune-activating properties, including anti-tumor activity.
